Authors
Nobuaki J Fukuma, Michael Brener, Michelle Hulke, Nobuaki Fukuma, Stephanie Golob, Robert Zilinyi, Zhipeng Zhou, Christos Tzimas, Ilaria Russo, Claire McGroder, Alexander Chong, Ryan Pfeiffer, Zhang Geping, Anne-Catrin Uhlemann, Jeffrey Moses, Martin Leon, Daniel Burkhoff, Mathew Maurer, Bjorn Redfors, Nir Uriel, Matthias Szabolcs, Charles C Marboe, Matthew Baldwin, Nathan R Tucker
Publication date
2021/11/16
Journal
Circulation
Volume
144
Issue
Suppl_1
Pages
A14422-A14422
Publisher
Lippincott Williams & Wilkins
Description
Cardiac microthrombi are postulated to underlie cardiac injury in critical COVID-19. To determine pathogenic mechanism(s) of cardiac injury in fatal COVID-19, we conducted a single-center prospective cohort study of 69 consecutive COVID-19 decedents. Microthrombi was the most commonly detected acute cardiac histopathologic feature (n=48, 70%). We tested associations of cardiac microthrombi with biomarkers of inflammation, cardiac injury, and fibrinolysis and with in-hospital antiplatelet therapy, therapeutic anticoagulation, and corticosteroid treatment, while adjusting for multiple clinical factors, including COVID-19 therapies. Higher peak ESR and CRP during hospitalization were independently associated with higher odds of microthrombi (ESR, Pnon-linearity 0.015, Passociation=0.008; CRP per 20mg/L increase, OR 1.17, 95%CI 1.00-1.36). Using single nuclei RNA-sequence analysis, we discovered an …